PMID: 16506351Mar 2, 2006Paper

Combating influenza with antiviral therapy in the pediatric population

Pharmacotherapy
Kara A Townsend, Lea S Eiland

Abstract

Influenza viruses are accountable for annual epidemics worldwide that result in significant morbidity and mortality. In preschool and school-aged children, prospective surveillance of influenza demonstrates yearly infection rates of 15-42%. Children can easily transmit the virus to other children, to employees in day-care and school settings, and to family members. Two classes of antiviral drugs, the adamantine derivatives (amantadine, rimantadine) and neuraminidase inhibitors (zanamivir and oseltamivir), have been approved for treatment and prophylaxis of influenza in the pediatric population. Duration of clinical symptoms decreases and daily activities are resumed sooner when therapy is begun within 48 hours of the onset of influenza symptoms. Mechanism of action, adverse effects, and development of resistant variants differ between the two drug classes. To our knowledge, head-to-head clinical trials between the classes and involving the neuraminidase inhibitors are nonexistent. Antiviral agents do not replace the annual influenza vaccine, and clinical trials indicate that amantadine, rimantadine, zanamivir, and oseltamivir are safe and effective for administration in the pediatric population.

References

Jun 1, 1988·The Pediatric Infectious Disease Journal·S A CrawfordR B Couch
Feb 1, 1986·Antimicrobial Agents and Chemotherapy·F G Hayden, A S Monto
Jan 1, 1986·European Journal of Clinical Pharmacology·M C Nahata, M T Brady
Sep 2, 1982·The New England Journal of Medicine·R DolinJ Webber-Jones
Oct 21, 1998·The Journal of Infectious Diseases·L V GubarevaR G Webster
Feb 27, 2001·The Pediatric Infectious Disease Journal·R J WhitleyP Ward
Aug 16, 2002·Occupational Medicine·D J StottW F Carman
Nov 29, 2002·Pediatrics·UNKNOWN Committee on Infectious Diseases. American Academy of Pediatrics
Dec 21, 2002·The Journal of Antimicrobial Chemotherapy·F Y AokiUNKNOWN IMPACT Study Group
Jun 28, 2003·Pediatrics International : Official Journal of the Japan Pediatric Society·Fusae ImutaTetsuya Toyoda
Aug 12, 2003·European Journal of Clinical Pharmacology·Charles OoPenelope Ward
May 15, 1964·Science·W L DAVIESC E HOFFMANN
Dec 4, 2004·The Pediatric Infectious Disease Journal·Frederick G Hayden
Dec 20, 2005·Journal of Preventive Medicine and Public Health = Yebang Ŭihakhoe Chi·Woo-Joo Kim

❮ Previous
Next ❯

Citations

Jan 17, 2007·Current Opinion in Pediatrics·Richard A Martinello
Aug 31, 2010·Paediatric Drugs·Steven M Smith, John G Gums
Nov 22, 2014·The Cochrane Database of Systematic Reviews·Márcia G Alves GalvãoAntonio J L Alves da Cunha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

Expert Opinion on Drug Safety
M Jones, Chis Del Mar
Seminars in Respiratory and Critical Care Medicine
Joseph P Lynch, Edward E Walsh
International Journal of Chronic Obstructive Pulmonary Disease
Patrick Mallia, Sebastian L Johnston
© 2021 Meta ULC. All rights reserved